posted on 2021-10-18, 18:11authored byRian M. Hasson
<p>Lung cancer is the leading cause of cancer death in the
United States, and it is estimated that smoking is the cause in approximately
80-90% of cases. Traditionally, tobacco prevention and cessation interventions
have been the focus of efforts designed to decrease lung cancer incidence and
mortality; unfortunately these programs are not always successful, and millions
of current and former smokers remain at substantial risk for diagnosis. While
researchers have more recently redirected their efforts to improving treatment
options, interventions targeting the earliest stages of lung cancer diagnosis
have proven most promising. Hence, shifting the focus from prevention and
smoking cessation to early detection appears to be vital to decrease this
disease’s threat.</p>
<p> </p>
<p>The need to identify factors that predict successful
enrollment of high-risk patients in early detection efforts is critical,
especially given known disparities in uptake. In 2011, the National Lung
Screening Trial (NLST) evaluated the utility of low-dose computed tomography
(LDCT) for screening those at high-risk for lung cancer. They demonstrated a
20% reduction in lung cancer-specific mortality and a 6.7% reduction in
all-cause mortality. This prompted 2012 guidelines recommending annual LDCT for
“high-risk” patients defined as those: (1) 55-80 years of age, (2) with at
least a 30 pack-year smoking history, (3) who are current smokers, or who have
quit in the last 15 years. Despite a second study replicating the results of
the NLST, today, lung cancer screening (LCS) is sadly under-utilized with less
than 5% of eligible patients participating. We know the effects of these
barriers are even more profound in less-populated areas. Hence, identification
of the motivators of participation are vital to decrease these disparities, and
interventions would benefit from prospective patient input.</p>